Insider Selling: Aveanna Healthcare (NASDAQ:AVAH) Major Shareholder Sells $8,000,000.00 in Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) major shareholder Robert Williams, Jr. sold 1,000,000 shares of the business’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $8.00, for a total transaction of $8,000,000.00. Following the sale, the insider directly owned 245,251 shares in the company, valued at approximately $1,962,008. This represents a 80.31% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Aveanna Healthcare Trading Down 0.3%

Shares of AVAH opened at $8.64 on Monday. The company has a current ratio of 1.47, a quick ratio of 1.47 and a debt-to-equity ratio of 5.35. The firm’s 50-day moving average is $7.14 and its two-hundred day moving average is $7.57. Aveanna Healthcare Holdings Inc. has a twelve month low of $3.73 and a twelve month high of $10.32. The firm has a market capitalization of $1.88 billion, a P/E ratio of 7.32, a PEG ratio of 0.89 and a beta of 1.93.

Aveanna Healthcare (NASDAQ:AVAH) last posted its quarterly earnings results on Thursday, May 14th. The company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.05. The company had revenue of $647.91 million during the quarter, compared to the consensus estimate of $613.22 million. Aveanna Healthcare had a net margin of 10.37% and a return on equity of 124.68%. Aveanna Healthcare’s revenue was up 15.9% on a year-over-year basis. On average, research analysts predict that Aveanna Healthcare Holdings Inc. will post 0.65 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on AVAH shares. Truist Financial lifted their price objective on Aveanna Healthcare from $8.00 to $9.00 and gave the stock a “hold” rating in a report on Wednesday, May 20th. Barclays dropped their price target on Aveanna Healthcare from $9.50 to $9.00 and set an “overweight” rating for the company in a research report on Monday, May 18th. BMO Capital Markets cut their price target on Aveanna Healthcare from $11.00 to $10.00 and set an “outperform” rating for the company in a research note on Friday, March 20th. Stephens upgraded shares of Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $10.00 to $11.00 in a research report on Friday, May 15th. Finally, Royal Bank Of Canada raised shares of Aveanna Healthcare from a “sector perform” rating to an “outperform” rating and set a $10.00 price objective on the stock in a research note on Wednesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $10.50.

Hedge Funds Weigh In On Aveanna Healthcare

Several hedge funds have recently bought and sold shares of the stock. AustralianSuper Pty Ltd acquired a new position in Aveanna Healthcare in the 3rd quarter valued at $15,743,000. Vanguard Group Inc. boosted its holdings in shares of Aveanna Healthcare by 38.0% during the fourth quarter. Vanguard Group Inc. now owns 5,577,010 shares of the company’s stock worth $45,564,000 after purchasing an additional 1,535,351 shares during the last quarter. Algert Global LLC grew its position in shares of Aveanna Healthcare by 120.1% in the third quarter. Algert Global LLC now owns 1,022,599 shares of the company’s stock valued at $9,070,000 after purchasing an additional 557,898 shares during the period. Quantbot Technologies LP grew its position in shares of Aveanna Healthcare by 1,220.8% in the third quarter. Quantbot Technologies LP now owns 109,707 shares of the company’s stock valued at $973,000 after purchasing an additional 101,401 shares during the period. Finally, UBS Group AG increased its stake in Aveanna Healthcare by 149.4% in the fourth quarter. UBS Group AG now owns 394,182 shares of the company’s stock valued at $3,220,000 after purchasing an additional 236,152 shares during the last quarter. Hedge funds and other institutional investors own 87.96% of the company’s stock.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.